Figure 2.
Figure 2. mAb CD69.2.2 induces CD69 internalization in activated lymphocytes in vitro and inhibition of CD69 expression in vivo. (A) CD69+ lymphocytes, previously stained with mAb CD69.2.2 antibodies and GAMalexa488, were incubated at 4°C or 37°C for 1 hour (left column). Incubation with PBS (pH 2.0; right column), removes membrane-bound mAbs. Representative photographs were taken by confocal microscopy. (B-C) C57BL/6 mice were treated at 8 weeks of age with a single injection (500 μg intraperitoneally) of mAb CD69.2.2 or control mAb (IgG1). Lymphocytes from treated mice were analyzed by flow cytometry. Representative profiles of B cells (B220/CD69) in lymph node (LN), spleen, and peritoneum 15 days after injection are shown (B). Bone marrow and LN lymphocytes (C) were subjected to flow cytometric analysis. Representative profiles of B220/IgM, IgD/IgM, LY6G/B220, and CD3/B220 are shown with the percentage of cells in each quadrant.

mAb CD69.2.2 induces CD69 internalization in activated lymphocytes in vitro and inhibition of CD69 expression in vivo. (A) CD69+ lymphocytes, previously stained with mAb CD69.2.2 antibodies and GAMalexa488, were incubated at 4°C or 37°C for 1 hour (left column). Incubation with PBS (pH 2.0; right column), removes membrane-bound mAbs. Representative photographs were taken by confocal microscopy. (B-C) C57BL/6 mice were treated at 8 weeks of age with a single injection (500 μg intraperitoneally) of mAb CD69.2.2 or control mAb (IgG1). Lymphocytes from treated mice were analyzed by flow cytometry. Representative profiles of B cells (B220/CD69) in lymph node (LN), spleen, and peritoneum 15 days after injection are shown (B). Bone marrow and LN lymphocytes (C) were subjected to flow cytometric analysis. Representative profiles of B220/IgM, IgD/IgM, LY6G/B220, and CD3/B220 are shown with the percentage of cells in each quadrant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal